CNS Pharmaceuticals holds virtual investor update; no specific results disclosed

CNS Pharmaceuticals, Inc.

Company held a virtual update meeting on Dec 21, 2023 with CEO John Climcao and CMO Dr. Sandra Silberman.
Meeting link provided in filing but no financial or clinical data included in the 8-K.
Filing under Regulation FD; no material new information furnished in the report.

item 7.01

CNS Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001683168-23-009006

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.